-- 
Israel Stocks: Avgol, Protalix, Tapuz, Teva Pharmaceutical, XTL

-- B y   S u s a n   L e r n e r   a n d   R o n i t   G o o d m a n
-- 
2011-03-24T15:47:08Z

-- http://www.bloomberg.com/news/2011-03-24/israel-stocks-avgol-industries-and-protalix-biotherapeutics.html
Israel ’s TA-25 Index dropped for a
second day, declining 0.3 percent to 1,280.44 at the 4:30 p.m.
close in Tel Aviv, trimming the gain for the week to 1 percent.
Investors traded about 3.37 billion shekels ($946.6 million) in
shares and convertible securities.  The following stocks rose or fell today. Symbols are in
parentheses.  Avgol Industries 1953 Ltd. (AVGL)   gained for the third
time this week, advancing 1.7 percent to 2.691 shekels. The
fabric manufacturer said fourth-quarter net income increased to
$5.5 million from $3.1 million.  Protalix BioTherapeutics Inc. (PLX)   increased for the
first time in five days, climbing 1.9 percent to 21.47 shekels.
The biotechnology company plans to start clinical trials of a
drug to treat Fabry disease this year and a medication against
rheumatoid arthritis in early 2012.  Tapuz People Ltd. (TPUZ)   rose to the highest level since
March 6, gaining 3.6 percent to 3.542 shekels. The designer of
Internet websites said 2010 net income rose to 3.69 million
shekels from 2.19 million shekels in 2009.  Teva Pharmaceutical Industries Ltd. (TEVA)   climbed the
most since Jan. 9, advancing 3.4 percent to 178.60 shekels. The
world’s largest maker of generic drugs agreed to form a
consumer-health venture with Procter & Gamble Co.  XTL Biopharmaceuticals Ltd. (XTLB)   soared the most since
March 9, jumping 8.6 percent to 0.504 shekel. The
biopharmaceutical company signed a letter of principles to
acquire an exclusive license to all of MinoGuard Ltd.’s
technology in exchange for royalty and milestone payments
throughout the clinical development process.  To contact the reporters on this story:
Susan Lerner in  Tel Aviv  at 
 slerner2@bloomberg.net ;
Ronit Goodman in Tel Aviv at 
 rgoodman9@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  